237 related articles for article (PubMed ID: 31073619)
1. Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment.
Ariëns LFM; van Nimwegen KJM; Shams M; de Bruin DT; van der Schaft J; van Os-Medendorp H; De Bruin-Weller M
Acta Derm Venereol; 2019 Jul; 99(9):762-768. PubMed ID: 31073619
[TBL] [Abstract][Full Text] [Related]
2. Economic and Humanistic Burden in Paediatric Patients with Atopic Dermatitis.
Achten R; Van der Rijst L; Piena M; Lamers H; De Beer F; De Bruin-Weller M; De Graaf M
Acta Derm Venereol; 2023 Mar; 103():adv00881. PubMed ID: 36883875
[TBL] [Abstract][Full Text] [Related]
3. Burden of Atopic dermatitis in Canada.
Barbeau M; Bpharm HL
Int J Dermatol; 2006 Jan; 45(1):31-6. PubMed ID: 16426372
[TBL] [Abstract][Full Text] [Related]
4. Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases.
Shrestha S; Miao R; Wang L; Chao J; Yuce H; Wei W
Adv Ther; 2017 Aug; 34(8):1989-2006. PubMed ID: 28707285
[TBL] [Abstract][Full Text] [Related]
5. The cost of atopic dermatitis in the Netherlands: an international comparison.
Verboom P; Hakkaart-Van L; Sturkenboom M; De Zeeuw R; Menke H; Rutten F
Br J Dermatol; 2002 Oct; 147(4):716-24. PubMed ID: 12366418
[TBL] [Abstract][Full Text] [Related]
6. Systematic literature review assessing the overall costs and societal impacts of moderate-to-severe atopic dermatitis in Europe.
Augustin M; Misery L; von Kobyletzski L; Mealing S; Redding M; Chuang CC; Massey R; Cawkwell M; Bego Le-Bagousse G; Haddy L; Rout R
J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):2316-2324. PubMed ID: 35920758
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
[TBL] [Abstract][Full Text] [Related]
8. A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitis.
Boguniewicz M; Abramovits W; Paller A; Whitaker-Worth DL; Prendergast M; Cheng JW; Wang P; Tong KB
J Drugs Dermatol; 2007 Apr; 6(4):416-23. PubMed ID: 17668539
[TBL] [Abstract][Full Text] [Related]
9. Societal costs and health related quality of life in adult atopic dermatitis.
Beretzky Z; Koszorú K; Rencz F; Hajdu K; Borza J; Bodai K; Feifei X; Szegedi A; Sárdy M; Brodszky V
BMC Health Serv Res; 2023 Aug; 23(1):859. PubMed ID: 37580792
[TBL] [Abstract][Full Text] [Related]
10. Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe.
Kotseva K; Gerlier L; Sidelnikov E; Kutikova L; Lamotte M; Amarenco P; Annemans L
Eur J Prev Cardiol; 2019 Jul; 26(11):1150-1157. PubMed ID: 30955367
[TBL] [Abstract][Full Text] [Related]
11. The humanistic and economic burden of atopic dermatitis among adults and adolescents in Saudi Arabia.
Elezbawy B; Fasseeh AN; Fouly E; Esba LCA; Al Abdulkarim H; Al-Haddab M; Al-Sheikh A; Altawil E; Al Turaiki A; Eshmawi M; Hamadah I; Tannira M; Dalle H; Aderian S; Roshdy A; Jaheen A; Hamad T; Abaza S; Kaló Z
J Med Econ; 2022; 25(1):1231-1239. PubMed ID: 36426726
[TBL] [Abstract][Full Text] [Related]
12. Economic Impact of Atopic Dermatitis in Adults: A Population-Based Study (IDEA Study).
Sicras-Mainar A; Navarro-Artieda R; Carrascosa Carrillo JM
Actas Dermosifiliogr (Engl Ed); 2018; 109(1):35-46. PubMed ID: 29126499
[TBL] [Abstract][Full Text] [Related]
13. A burden of illness study for neuropathic pain in Europe.
Liedgens H; Obradovic M; De Courcy J; Holbrook T; Jakubanis R
Clinicoecon Outcomes Res; 2016; 8():113-26. PubMed ID: 27217785
[TBL] [Abstract][Full Text] [Related]
14. Economic burden and productivity loss related to eczema: A prevalence-based follow-up study in Vietnam.
Le PH; Vo TQ
J Pak Med Assoc; 2019 Jun; 69(Suppl 2)(6):S57-S63. PubMed ID: 31369535
[TBL] [Abstract][Full Text] [Related]
15. Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS-J): Baseline characteristics, treatment history and disease burden.
Katoh N; Saeki H; Kataoka Y; Etoh T; Teramukai S; Takagi H; Tajima Y; Ardeleanu M; Rizova E; Arima K;
J Dermatol; 2019 Apr; 46(4):290-300. PubMed ID: 30756423
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of maintenance treatment with tacrolimus 0.1% ointment in adults with moderate to severe atopic dermatitis.
Wollenberg A; Sidhu MK; Odeyemi I; Dorsch B; Koehne-Volland R; Schaff M; Ehlken B; Berger K
Br J Dermatol; 2008 Dec; 159(6):1322-30. PubMed ID: 18782316
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoeconomics of drug therapy for atopic dermatitis.
Lamb SR; Rademaker M
Expert Opin Pharmacother; 2002 Mar; 3(3):249-55. PubMed ID: 11866675
[TBL] [Abstract][Full Text] [Related]
18. Unveiling the true costs and societal impacts of moderate-to-severe atopic dermatitis in Europe.
Augustin M; Misery L; von Kobyletzki L; Armario-Hita JC; Mealing S; Redding M
J Eur Acad Dermatol Venereol; 2022 Jul; 36 Suppl 7():3-16. PubMed ID: 35801296
[TBL] [Abstract][Full Text] [Related]
19. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β
Pavord ID; Mathieson N; Scowcroft A; Pedersini R; Isherwood G; Price D
NPJ Prim Care Respir Med; 2017 Mar; 27(1):17. PubMed ID: 28270657
[TBL] [Abstract][Full Text] [Related]
20. Health Care Resource Utilization and Costs Among Adults with Atopic Dermatitis in the United States: A Claims-Based Analysis.
Drucker AM; Qureshi AA; Amand C; Villeneuve S; Gadkari A; Chao J; Kuznik A; Bégo-Le-Bagousse G; Eckert L
J Allergy Clin Immunol Pract; 2018; 6(4):1342-1348. PubMed ID: 29174063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
